Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study
Identifieur interne : 003073 ( PascalFrancis/Checkpoint ); précédent : 003072; suivant : 003074Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study
Auteurs : Nicolas Andre [France] ; Angelique Rome [France] ; Carole Coze [France] ; Laetitia Padovani [France] ; Eddy Pasquier [France, Australie] ; Laurence Camoin [France] ; Jean Claude Gentet [France]Source :
- Clinical therapeutics [ 0149-2918 ] ; 2008.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Enfant.
English descriptors
- KwdEn :
Abstract
Background: Metronomic chemotherapy (MC) is the administration of chemotherapy at doses below the maximal tolerated dose on a frequent schedule of administration, with no prolonged drug-free breaks. Objective: The aim of this research was to assess the effectiveness and tolerance of a metronomic etoposide/ cyclophosphamide/celecoxib regimen in children and adolescents with refractory cancer. Methods: This retrospective, single-center study evaluated the use of MC with etoposide 25 mg/m2. d-1 (days 1-14), cyclophosphamide 25 mg/m2. d-1 (days 15-28), and celecoxib 100 to 400 mg/d (days 1-28), in children with refractory, or high-risk relapsing, cancer. Adverse events were determined through laboratory analyses and investigator observations. Results: From January 2005 to December 2007, 17 children and adolescents were treated. The best responses observed were stabilizations of the disease that lasted over 20 weeks in 7 patients (41%). Most importantly, in 4 patients (24%) antalgic treatment could be transiently diminished or stopped, and in 1 patient (6%) oxygen support could be stopped for several weeks. Four grade IV platelet toxicities were noted in 3 patients; 2 grade IV anemia occurred in 2 patients (who had platelet and red blood cell transfusions before initiation of treatment); and 1 patient had grade III neutropenia. No other grade III or IV toxicities were noted. Grade II alopecia and stomatitis were observed in 1 patient and grade II vomiting was observed in 2 patients. One patient with meningeal carcinomatosis developed bilateral subdural hematoma for which the role of MC could not be ruled out. Circulating endothelial cells were elevated in 3 out of 3 patients in whom they were quantified and who were progressing while under MC. Conclusion: The MC regimen we report here was associated with disease stabilization without major toxicities. This assessment of MC in children and adolescents warrants further studies.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:08-0399816Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study</title><author><name sortKey="Andre, Nicolas" sort="Andre, Nicolas" uniqKey="Andre N" first="Nicolas" last="Andre">Nicolas Andre</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université d'Aix-Marseille</orgName></affiliation></author><author><name sortKey="Rome, Angelique" sort="Rome, Angelique" uniqKey="Rome A" first="Angelique" last="Rome">Angelique Rome</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Coze, Carole" sort="Coze, Carole" uniqKey="Coze C" first="Carole" last="Coze">Carole Coze</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Padovani, Laetitia" sort="Padovani, Laetitia" uniqKey="Padovani L" first="Laetitia" last="Padovani">Laetitia Padovani</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Service de Radiothérapie, Hôpital de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Pasquier, Eddy" sort="Pasquier, Eddy" uniqKey="Pasquier E" first="Eddy" last="Pasquier">Eddy Pasquier</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université d'Aix-Marseille</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Children's Cancer Institute Australia, Pharmacoproteomics Croup, Children's Hospital</s1><s2>Randwick</s2><s3>AUS</s3><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Randwick</wicri:noRegion></affiliation></author><author><name sortKey="Camoin, Laurence" sort="Camoin, Laurence" uniqKey="Camoin L" first="Laurence" last="Camoin">Laurence Camoin</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Laboratoire d'hématologie, Hôpital de la Conception</s1><s2>Marseille</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Gentet, Jean Claude" sort="Gentet, Jean Claude" uniqKey="Gentet J" first="Jean Claude" last="Gentet">Jean Claude Gentet</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0399816</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0399816 INIST</idno><idno type="RBID">Pascal:08-0399816</idno><idno type="wicri:Area/PascalFrancis/Corpus">003365</idno><idno type="wicri:Area/PascalFrancis/Curation">002C87</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003073</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003073</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study</title><author><name sortKey="Andre, Nicolas" sort="Andre, Nicolas" uniqKey="Andre N" first="Nicolas" last="Andre">Nicolas Andre</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université d'Aix-Marseille</orgName></affiliation></author><author><name sortKey="Rome, Angelique" sort="Rome, Angelique" uniqKey="Rome A" first="Angelique" last="Rome">Angelique Rome</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Coze, Carole" sort="Coze, Carole" uniqKey="Coze C" first="Carole" last="Coze">Carole Coze</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Padovani, Laetitia" sort="Padovani, Laetitia" uniqKey="Padovani L" first="Laetitia" last="Padovani">Laetitia Padovani</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Service de Radiothérapie, Hôpital de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Pasquier, Eddy" sort="Pasquier, Eddy" uniqKey="Pasquier E" first="Eddy" last="Pasquier">Eddy Pasquier</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université d'Aix-Marseille</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Children's Cancer Institute Australia, Pharmacoproteomics Croup, Children's Hospital</s1><s2>Randwick</s2><s3>AUS</s3><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Randwick</wicri:noRegion></affiliation></author><author><name sortKey="Camoin, Laurence" sort="Camoin, Laurence" uniqKey="Camoin L" first="Laurence" last="Camoin">Laurence Camoin</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Laboratoire d'hématologie, Hôpital de la Conception</s1><s2>Marseille</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Gentet, Jean Claude" sort="Gentet, Jean Claude" uniqKey="Gentet J" first="Jean Claude" last="Gentet">Jean Claude Gentet</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Clinical therapeutics</title><title level="j" type="abbreviated">Clin. ther.</title><idno type="ISSN">0149-2918</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Clinical therapeutics</title><title level="j" type="abbreviated">Clin. ther.</title><idno type="ISSN">0149-2918</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Antineoplastic agent</term><term>Cancerology</term><term>Celecoxib</term><term>Child</term><term>Cyclophosphamide</term><term>Endothelial cell</term><term>Etoposide</term><term>Malignant tumor</term><term>Metronomic chemotherapy</term><term>Non steroidal antiinflammatory agent</term><term>Therapeutic protocol</term><term>Treatment resistance</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Etoposide</term><term>Cyclophosphamide</term><term>Anticancéreux</term><term>Célécoxib</term><term>Protocole thérapeutique</term><term>Enfant</term><term>Adolescent</term><term>Résistance traitement</term><term>Tumeur maligne</term><term>Cancérologie</term><term>Cellule endothéliale</term><term>Antiinflammatoire non stéroïde</term><term>Gène sis</term><term>Chimiothérapie métronomique</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Enfant</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Metronomic chemotherapy (MC) is the administration of chemotherapy at doses below the maximal tolerated dose on a frequent schedule of administration, with no prolonged drug-free breaks. Objective: The aim of this research was to assess the effectiveness and tolerance of a metronomic etoposide/ cyclophosphamide/celecoxib regimen in children and adolescents with refractory cancer. Methods: This retrospective, single-center study evaluated the use of MC with etoposide 25 mg/m<sup>2</sup>. d<sup>-1</sup> (days 1-14), cyclophosphamide 25 mg/m<sup>2</sup>. d<sup>-1</sup> (days 15-28), and celecoxib 100 to 400 mg/d (days 1-28), in children with refractory, or high-risk relapsing, cancer. Adverse events were determined through laboratory analyses and investigator observations. Results: From January 2005 to December 2007, 17 children and adolescents were treated. The best responses observed were stabilizations of the disease that lasted over 20 weeks in 7 patients (41%). Most importantly, in 4 patients (24%) antalgic treatment could be transiently diminished or stopped, and in 1 patient (6%) oxygen support could be stopped for several weeks. Four grade IV platelet toxicities were noted in 3 patients; 2 grade IV anemia occurred in 2 patients (who had platelet and red blood cell transfusions before initiation of treatment); and 1 patient had grade III neutropenia. No other grade III or IV toxicities were noted. Grade II alopecia and stomatitis were observed in 1 patient and grade II vomiting was observed in 2 patients. One patient with meningeal carcinomatosis developed bilateral subdural hematoma for which the role of MC could not be ruled out. Circulating endothelial cells were elevated in 3 out of 3 patients in whom they were quantified and who were progressing while under MC. Conclusion: The MC regimen we report here was associated with disease stabilization without major toxicities. This assessment of MC in children and adolescents warrants further studies.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0149-2918</s0></fA01><fA03 i2="1"><s0>Clin. ther.</s0></fA03><fA05><s2>30</s2></fA05><fA06><s2>7</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study</s1></fA08><fA11 i1="01" i2="1"><s1>ANDRE (Nicolas)</s1></fA11><fA11 i1="02" i2="1"><s1>ROME (Angelique)</s1></fA11><fA11 i1="03" i2="1"><s1>COZE (Carole)</s1></fA11><fA11 i1="04" i2="1"><s1>PADOVANI (Laetitia)</s1></fA11><fA11 i1="05" i2="1"><s1>PASQUIER (Eddy)</s1></fA11><fA11 i1="06" i2="1"><s1>CAMOIN (Laurence)</s1></fA11><fA11 i1="07" i2="1"><s1>GENTET (Jean Claude)</s1></fA11><fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="02"><s1>INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="03"><s1>Service de Radiothérapie, Hôpital de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="04"><s1>Children's Cancer Institute Australia, Pharmacoproteomics Croup, Children's Hospital</s1><s2>Randwick</s2><s3>AUS</s3><sZ>5 aut.</sZ></fA14><fA14 i1="05"><s1>Laboratoire d'hématologie, Hôpital de la Conception</s1><s2>Marseille</s2><s3>FRA</s3><sZ>6 aut.</sZ></fA14><fA20><s1>1336-1340</s1></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18353</s2><s5>354000196281980150</s5></fA43><fA44><s0>0000</s0><s1>© 2008 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>12 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>08-0399816</s0></fA47><fA60><s1>P</s1><s3>CR</s3></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Clinical therapeutics</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: Metronomic chemotherapy (MC) is the administration of chemotherapy at doses below the maximal tolerated dose on a frequent schedule of administration, with no prolonged drug-free breaks. Objective: The aim of this research was to assess the effectiveness and tolerance of a metronomic etoposide/ cyclophosphamide/celecoxib regimen in children and adolescents with refractory cancer. Methods: This retrospective, single-center study evaluated the use of MC with etoposide 25 mg/m<sup>2</sup>. d<sup>-1</sup> (days 1-14), cyclophosphamide 25 mg/m<sup>2</sup>. d<sup>-1</sup> (days 15-28), and celecoxib 100 to 400 mg/d (days 1-28), in children with refractory, or high-risk relapsing, cancer. Adverse events were determined through laboratory analyses and investigator observations. Results: From January 2005 to December 2007, 17 children and adolescents were treated. The best responses observed were stabilizations of the disease that lasted over 20 weeks in 7 patients (41%). Most importantly, in 4 patients (24%) antalgic treatment could be transiently diminished or stopped, and in 1 patient (6%) oxygen support could be stopped for several weeks. Four grade IV platelet toxicities were noted in 3 patients; 2 grade IV anemia occurred in 2 patients (who had platelet and red blood cell transfusions before initiation of treatment); and 1 patient had grade III neutropenia. No other grade III or IV toxicities were noted. Grade II alopecia and stomatitis were observed in 1 patient and grade II vomiting was observed in 2 patients. One patient with meningeal carcinomatosis developed bilateral subdural hematoma for which the role of MC could not be ruled out. Circulating endothelial cells were elevated in 3 out of 3 patients in whom they were quantified and who were progressing while under MC. Conclusion: The MC regimen we report here was associated with disease stabilization without major toxicities. This assessment of MC in children and adolescents warrants further studies.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Etoposide</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Etoposide</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Etopósido</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Cyclophosphamide</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Cyclophosphamide</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Ciclofosfamida</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Anticancéreux</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Antineoplastic agent</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Anticanceroso</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Célécoxib</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Celecoxib</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Celecoxib</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Protocole thérapeutique</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Therapeutic protocol</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Protocolo terapéutico</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Enfant</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Child</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Niño</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Adolescent</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Adolescent</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Adolescente</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Résistance traitement</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Treatment resistance</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Resistencia tratamiento</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Cancérologie</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Cancerology</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Cancerología</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Cellule endothéliale</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Endothelial cell</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Célula endotelial</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Antiinflammatoire non stéroïde</s0><s5>23</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Non steroidal antiinflammatory agent</s0><s5>23</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Antiinflamatorio no esteroide</s0><s5>23</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Gène sis</s0><s4>INC</s4><s5>86</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Chimiothérapie métronomique</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Metronomic chemotherapy</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Human</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Antimitotique</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Antimitotic</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Antimitótico</s0><s5>37</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>DNA topoisomerase (ATP-hydrolysing)</s0><s2>FE</s2><s5>38</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>DNA topoisomerase (ATP-hydrolysing)</s0><s2>FE</s2><s5>38</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>DNA topoisomerase (ATP-hydrolysing)</s0><s2>FE</s2><s5>38</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Isomerases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Isomerases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Isomerases</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0><s5>39</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Enzyme inhibitor</s0><s5>39</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Inhibidor enzima</s0><s5>39</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Dérivé de la podophyllotoxine</s0><s5>40</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Podophyllotoxin derivatives</s0><s5>40</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Podofilotoxina derivado</s0><s5>40</s5></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Inhibiteur de la topoisomérase II</s0><s5>41</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Topoisomerase II inhibitor</s0><s5>41</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Inhibidor topoisomerase II</s0><s5>41</s5></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Agent alkylant</s0><s5>42</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Alkylating agent</s0><s5>42</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Agente alquilante</s0><s5>42</s5></fC07><fC07 i1="11" i2="X" l="FRE"><s0>Moutarde à l'azote</s0><s5>43</s5></fC07><fC07 i1="11" i2="X" l="ENG"><s0>Nitrogen mustard</s0><s5>43</s5></fC07><fC07 i1="11" i2="X" l="SPA"><s0>Mostaza al nitrógeno</s0><s5>43</s5></fC07><fC07 i1="12" i2="X" l="FRE"><s0>Dérivé de l'oxazaphosphinane</s0><s5>44</s5></fC07><fC07 i1="12" i2="X" l="ENG"><s0>Oxazaphosphinane derivatives</s0><s5>44</s5></fC07><fC07 i1="12" i2="X" l="SPA"><s0>Oxazafosfinano derivado</s0><s5>44</s5></fC07><fC07 i1="13" i2="X" l="FRE"><s0>Inhibiteur cyclooxygenase 2</s0><s5>45</s5></fC07><fC07 i1="13" i2="X" l="ENG"><s0>Cyclooxygenase 2 inhibitor</s0><s5>45</s5></fC07><fC07 i1="13" i2="X" l="SPA"><s0>Inhibidor cyclooxygenase 2</s0><s5>45</s5></fC07><fC07 i1="14" i2="X" l="FRE"><s0>Prostaglandin-endoperoxide synthase</s0><s2>FE</s2><s5>46</s5></fC07><fC07 i1="14" i2="X" l="ENG"><s0>Prostaglandin-endoperoxide synthase</s0><s2>FE</s2><s5>46</s5></fC07><fC07 i1="14" i2="X" l="SPA"><s0>Prostaglandin-endoperoxide synthase</s0><s2>FE</s2><s5>46</s5></fC07><fC07 i1="15" i2="X" l="FRE"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="15" i2="X" l="ENG"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="15" i2="X" l="SPA"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fN21><s1>259</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Marseille</li></settlement><orgName><li>Université d'Aix-Marseille</li></orgName></list><tree><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Andre, Nicolas" sort="Andre, Nicolas" uniqKey="Andre N" first="Nicolas" last="Andre">Nicolas Andre</name></region><name sortKey="Andre, Nicolas" sort="Andre, Nicolas" uniqKey="Andre N" first="Nicolas" last="Andre">Nicolas Andre</name><name sortKey="Camoin, Laurence" sort="Camoin, Laurence" uniqKey="Camoin L" first="Laurence" last="Camoin">Laurence Camoin</name><name sortKey="Coze, Carole" sort="Coze, Carole" uniqKey="Coze C" first="Carole" last="Coze">Carole Coze</name><name sortKey="Gentet, Jean Claude" sort="Gentet, Jean Claude" uniqKey="Gentet J" first="Jean Claude" last="Gentet">Jean Claude Gentet</name><name sortKey="Padovani, Laetitia" sort="Padovani, Laetitia" uniqKey="Padovani L" first="Laetitia" last="Padovani">Laetitia Padovani</name><name sortKey="Pasquier, Eddy" sort="Pasquier, Eddy" uniqKey="Pasquier E" first="Eddy" last="Pasquier">Eddy Pasquier</name><name sortKey="Rome, Angelique" sort="Rome, Angelique" uniqKey="Rome A" first="Angelique" last="Rome">Angelique Rome</name></country><country name="Australie"><noRegion><name sortKey="Pasquier, Eddy" sort="Pasquier, Eddy" uniqKey="Pasquier E" first="Eddy" last="Pasquier">Eddy Pasquier</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003073 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 003073 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:08-0399816
|texte= Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study
}}
| This area was generated with Dilib version V0.6.33. |  |